Printer Friendly

SYNERGEN APPOINTS HEADS OF CLINICAL RESEARCH AND REGULATORY AFFAIRS IN EUROPE

 BOULDER, Colo., Jan. 6 /PRNewswire/ -- Synergen Inc. (NASDAQ: SYGN) announced today the appointment of Dr. Giles V. Campion, as associate director, clinical research and Dr. Kathleen Joanna Tufnell, as associate director, regulatory affairs in Europe.
 In this newly created position, Campion will develop and implement clinical trials for all Synergen products in Europe. "Dr. Campion brings us the training from academia and industry we need to prepare for conducting clinical trials in European countries. We are fortunate to have attracted someone of his experience as we expand our drug development efforts in Europe," said Michael A. Catalano, M.D., vice president of corporate clinical research at Synergen.
 Campion joined Synergen from Hoechst AG in Germany, where he held the position as head, section of rheumatology research. While at Hoechst, Campion held an Honorary Post in the Rheumatology Unit at the Bristol Royal Infirmary in the United Kingdom. Receiving his medical and doctorate degrees from Bristol University Medical School, Campion has authored two books, several book chapters and many peer-review articles in the area of rheumatology.
 Tufnell comes to Synergen from the Medicines Control Agency (MCA) in the United Kingdom where she was principal pharmaceutical officer in the biological unit. Prior to her appointments with the MCA, Tufnell conducted postgraduate research and served as lecturer and instructor at University of Bath in Avon.
 Tufnell's primary responsibilities at Synergen will be to manage the submission of product license applications for all products and to coordinate with regulatory agencies throughout Europe. "Hiring Dr. Tufnell is an integral part of Synergen's plan to become an independent, multinational biopharmaceutical company in Europe," said Nigel Goodman, director of marketing and business affairs for Synergen Europe.
 Synergen is a biopharmaceutical company engaged in the discovery, development and manufacture of protein-based pharmaceuticals. The company's research is targeted toward products for inflammatory diseases, tissue repair and neurological diseases. The company is headquartered in Boulder with manufacturing facilities in Boulder, Delaware and operations in The Hague and Kobe, Japan.
 -0- 1/6/93
 /CONTACT: Paul Laland (Media), 303-541-1325; or Debra Bannister (Financial), 303-938-6242, both of Synergen/
 (SYGN)


CO: Synergen Inc. ST: Colorado IN: MTC SU: PER

BB -- DV001 -- 2045 01/06/93 08:17 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 6, 1993
Words:365
Previous Article:WILCOCK NAMED PRESIDENT OF DOW'S PACIFIC AREA
Next Article:DAY RUNNER(R) ANNOUNCES ESTIMATED FOURTH QUARTER SALES
Topics:


Related Articles
SYNERGEN AWARDED THIRD CNTF PATENT
SYNERGEN TO PRESENT ANTRIL PHASE III SEPSIS TRIAL RESULTS
SYNERGEN REPORTS MANAGEMENT CHANGES
SYNERGEN REPORTS FIRST QUARTER FINANCIAL RESULTS
SYNERGEN INC. REPORTS THIRD QUARTER FINANCIAL RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters